Eli Lilly has engaged in a $1.3 billion partnership with Superluminal Medicines to innovate small-molecule drugs targeting obesity and cardiometabolic diseases. The agreement provides Lilly access to Superluminal's AI-driven platform for rapid drug discovery that focuses on GPCRs, which have a vital role in many physiological processes. Lilly seeks to enhance its robust standing in a market projected to grow to $150 billion. Under this deal, Superluminal will receive payments and royalties as Lilly obtains exclusive rights to develop and commercialize discovered drug candidates.
Eli Lilly's $1.3 billion agreement with Superluminal Medicines focuses on discovering AI-driven small-molecule drugs for obesity and cardiometabolic diseases, enhancing Lilly's market presence.
The deal allows Eli Lilly to utilize Superluminal's proprietary AI platform, aimed at discovering drugs that target GPCRs, crucial for various physiological functions, particularly in obesity treatment.
Lilly aims to strengthen its standing in the obesity market, projected to reach $150 billion, through innovative drug development, acquisitions, and strategic partnerships.
Superluminal is set to receive milestone payments and royalties from drug sales, while Lilly secures exclusive rights to any drugs developed through this collaboration.
#eli-lilly #superluminal-medicines #obesity-treatment #cardiometabolic-diseases #ai-in-drug-discovery
Collection
[
|
...
]